Welcome to the News You Might Have Missed, a weekly roundup of news items to help you catch up and stay informed.
It was a busy week with lots of news, have a look and see you next week for another update.
PharmaTher Granted FDA Orphan Drug Designation For Ketamine To Treat Amyotrophic Lateral Sclerosis
The Company announced that the U.S. Food and Drug Administration has granted orphan drug designation (ODD) for ketamine in the treatment of Amyotrophic Lateral Sclerosis (ALS), also known as Lou Gehrig’s disease. Read more
Levitee Labs Completes Acquisition of Earth Circle Organics, Adds Superfoods Company to Portfolio
The acquisition adds 180+ SKUs across three brands to the Levitee portfolio: Earth Circle Organics, Earth Shift Products, and Ojio. Read more
Wesana Health Announces Listing on OTCQB® Venture Market
The company has received approval from the OTC Markets to begin trading on the OTCQB® Venture Market (“OTCQB”) as of August 2nd, 2021 under the ticker symbol “WSNAF”. Read more
Filament Health is the First Public Company to be Issued Patent for Extraction of Natural Psilocybin
The company announced that it is the first public company to be issued a patent by the Canadian Intellectual Property Office for the extraction and standardization of natural psilocybin and associated psychoactive compounds. Read more
The proceeds will allow Psygen to hire key employees and complete their 17,000 square foot facility, which is anticipated to be the first GMP compliant manufacturing facility dedicated to synthetic production of psychedelics when construction is completed in Q3, 2021. Read more
Awakn Life Sciences Announces Its Second Location in the UK for “Awakn Clinics London”
The clinic will deliver psychedelic-assisted psychotherapy treatments for Addiction and other mental health conditions and is scheduled to open during the fourth quarter of 2021. Read more
NeonMind Announces Corporate Update and Strategic Reorganization of its Pharmaceutical Division
The company announced today a strategic reorganization to focus on the execution of the Company’s integrated drug development plan (“IDP”) for its lead drug candidate targeting obesity, NEO-001. Read more